PolTREG Initiates Phase 2 Clinical Trial for Pediatric Diabetes Therapy
Recently, PolTREG S.A., an innovative biotechnology company focused on cellular therapies, has embarked on an exciting new Phase 2 clinical trial to investigate the efficacy of PTG-007 for children at high genetic risk of developing type 1 diabetes (T1D). By targeting the disease at a presymptomatic stage, the company aims to transform diabetes care and possibly provide a functional cure.
Overview of the Clinical Trial
The trial, now underway after receiving the green light from regulatory authorities, will involve a placebo-controlled study on 150 participants between the ages of six and sixteen. These patients have a genetic predisposition for T1D but haven't exhibited any symptoms yet. Initial clinical sites have begun operations, and recruitment processes for patients will commence shortly.
Significance of Early Intervention
Currently, once children are diagnosed with diabetes, they typically experience significant loss of pancreatic islet cells responsible for insulin production. Prof. Piotr Trzonkowski, CEO of PolTREG, emphasizes the importance of administering PTG-007 early in the disease process when sufficient islet cells still exist. This approach could prevent the onset of diabetes symptoms, enabling healthy living without the burden of ongoing treatment.
Funding and Support for the Study
To support this vital research, PolTREG has secured a substantial grant of 31.7 million zloty (approximately €7.3 million) from Poland’s Medical Research Agency. With over a decade’s worth of safety and efficacy data for PTG-007, the company is uniquely positioned in the arena of T1D therapies. The gathered data indicates that a notable percentage of patients maintained insulin independence and remained in clinical remission for years post-treatment.
Extending the Research Horizon
PolTREG is on the verge of launching a pivotal Phase 2/3 trial for early-onset T1D and is actively seeking additional funding sources. This endeavor complements its long-standing focus on establishing effective therapies for autoimmune diseases.
PolTREG's Innovation in Autoimmune Therapies
PTG-007 is categorized as an Advanced Therapy Medicinal Product (ATMP) and is a cornerstone of PolTREG’s approach to developing treatments for autoimmune conditions. The company has also conducted several clinical trials involving other diseases, such as multiple sclerosis and graft-versus-host disease, showcasing its innovative capabilities in the field.
Proprietary Development of Treg Modalities
What sets PolTREG apart is its ability to develop various Treg modalities in-house, including CAR-Treg and engineered Treg cells. These advancements, complemented by their extensive clinical trial experience, position PolTREG to accelerate the development of new therapies and bring them to market rapidly.
About PolTREG
As a leader in the field of autoimmune therapies, PolTREG specializes in treatments derived from T-regulatory cells. Its flagship therapy, PTG-007, is preparing for extensive clinical testing, with plans to initiate further trials aimed at treating multiple sclerosis in late 2024. Additionally, the company is at the forefront of designing novel engineered Treg therapies, expanding its potential to address a myriad of autoimmune disorders.
Contact Information
For further inquiries, individuals can reach out to:
PolTREG S.A.
Prof. Piotr Trzonkowski
Chief Executive Officer
Email: ir@poltreg.com
Phone: +48 512 532 401
Investor Relations
Frank Hoerning-Andersen
Cohesion Bureau
Phone: +45 25 66 86 02
Email: frank.hoerning@cohesionbureau.com
Media Relations
Douwe Miedema
Cohesion Bureau
Phone: +352 621 562 764
Email: douwe.miedema@cohesionbureau.com
Frequently Asked Questions
What is the purpose of PolTREG's Phase 2 Trial?
The trial aims to evaluate the safety and efficacy of PTG-007 Treg cell therapy in children at high risk of developing type 1 diabetes.
How many participants are involved in the trial?
150 patients, aged between 6 and 16 years, will participate in the study.
What funding has PolTREG received for this study?
PolTREG has secured a grant of 31.7 million zloty (€7.3 million) from Poland's Medical Research Agency.
What are some other conditions PolTREG is researching?
In addition to type 1 diabetes, PolTREG is developing therapies for multiple sclerosis and graft-versus-host disease.
What makes PTG-007 unique?
PTG-007 is a proprietary Treg therapy with over 12 years of safety and efficacy data, making it a significant advancement in the treatment of autoimmune diseases.
